“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements

Yannick Palmowski, Thomas Buttgereit, Christian Dejaco, Johannes W. Bijlsma, Eric Lawrence Matteson, Marieke Voshaar, Maarten Boers, Frank Buttgereit

Research output: Contribution to journalArticle

15 Citations (Scopus)

Abstract

Objective: To describe the perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects. Methods: We conducted a systematic literature review using the databases Ovid Embase, PubMed Medline, and Cochrane Library for guidelines on the pharmacologic treatment of RA. Retrieved articles were evaluated regarding their quality using the Appraisal of Guidelines for Research and Evaluation II tool and scrutinized for all relevant information concerning the use of glucocorticoids. Results: All guidelines agree that glucocorticoids, especially if given at low doses and for a short duration, are an appropriate option in the treatment of RA. However, many recommendations remain vague, as reliable and detailed evidence is scarce. Important aspects of glucocorticoid therapy are partially or completely neglected, and the existing nomenclature is not used uniformly. Quality evaluation revealed flaws in many articles, concerning not only glucocorticoid-specific recommendations but also guideline quality in general. Conclusion: Current recommendations for use of glucocorticoids in the management of RA are suboptimal. More rigorous evaluation of doses, timing, and duration of their use is needed. Existing nomenclature on glucocorticoid therapy should be used uniformly.

Original languageEnglish (US)
Pages (from-to)1134-1141
Number of pages8
JournalArthritis Care and Research
Volume69
Issue number8
DOIs
StatePublished - Aug 1 2017

Fingerprint

Glucocorticoids
Rheumatoid Arthritis
Consensus
Guidelines
Terminology
PubMed
Libraries
Databases
Therapeutics
Research

ASJC Scopus subject areas

  • Rheumatology

Cite this

“Official View” on Glucocorticoids in Rheumatoid Arthritis : A Systematic Review of International Guidelines and Consensus Statements. / Palmowski, Yannick; Buttgereit, Thomas; Dejaco, Christian; Bijlsma, Johannes W.; Matteson, Eric Lawrence; Voshaar, Marieke; Boers, Maarten; Buttgereit, Frank.

In: Arthritis Care and Research, Vol. 69, No. 8, 01.08.2017, p. 1134-1141.

Research output: Contribution to journalArticle

Palmowski, Yannick ; Buttgereit, Thomas ; Dejaco, Christian ; Bijlsma, Johannes W. ; Matteson, Eric Lawrence ; Voshaar, Marieke ; Boers, Maarten ; Buttgereit, Frank. / “Official View” on Glucocorticoids in Rheumatoid Arthritis : A Systematic Review of International Guidelines and Consensus Statements. In: Arthritis Care and Research. 2017 ; Vol. 69, No. 8. pp. 1134-1141.
@article{d2692fdffd21417a8780d19f0d176419,
title = "“Official View” on Glucocorticoids in Rheumatoid Arthritis: A Systematic Review of International Guidelines and Consensus Statements",
abstract = "Objective: To describe the perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects. Methods: We conducted a systematic literature review using the databases Ovid Embase, PubMed Medline, and Cochrane Library for guidelines on the pharmacologic treatment of RA. Retrieved articles were evaluated regarding their quality using the Appraisal of Guidelines for Research and Evaluation II tool and scrutinized for all relevant information concerning the use of glucocorticoids. Results: All guidelines agree that glucocorticoids, especially if given at low doses and for a short duration, are an appropriate option in the treatment of RA. However, many recommendations remain vague, as reliable and detailed evidence is scarce. Important aspects of glucocorticoid therapy are partially or completely neglected, and the existing nomenclature is not used uniformly. Quality evaluation revealed flaws in many articles, concerning not only glucocorticoid-specific recommendations but also guideline quality in general. Conclusion: Current recommendations for use of glucocorticoids in the management of RA are suboptimal. More rigorous evaluation of doses, timing, and duration of their use is needed. Existing nomenclature on glucocorticoid therapy should be used uniformly.",
author = "Yannick Palmowski and Thomas Buttgereit and Christian Dejaco and Bijlsma, {Johannes W.} and Matteson, {Eric Lawrence} and Marieke Voshaar and Maarten Boers and Frank Buttgereit",
year = "2017",
month = "8",
day = "1",
doi = "10.1002/acr.23185",
language = "English (US)",
volume = "69",
pages = "1134--1141",
journal = "Arthritis and Rheumatology",
issn = "2326-5191",
publisher = "John Wiley and Sons Ltd",
number = "8",

}

TY - JOUR

T1 - “Official View” on Glucocorticoids in Rheumatoid Arthritis

T2 - A Systematic Review of International Guidelines and Consensus Statements

AU - Palmowski, Yannick

AU - Buttgereit, Thomas

AU - Dejaco, Christian

AU - Bijlsma, Johannes W.

AU - Matteson, Eric Lawrence

AU - Voshaar, Marieke

AU - Boers, Maarten

AU - Buttgereit, Frank

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Objective: To describe the perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects. Methods: We conducted a systematic literature review using the databases Ovid Embase, PubMed Medline, and Cochrane Library for guidelines on the pharmacologic treatment of RA. Retrieved articles were evaluated regarding their quality using the Appraisal of Guidelines for Research and Evaluation II tool and scrutinized for all relevant information concerning the use of glucocorticoids. Results: All guidelines agree that glucocorticoids, especially if given at low doses and for a short duration, are an appropriate option in the treatment of RA. However, many recommendations remain vague, as reliable and detailed evidence is scarce. Important aspects of glucocorticoid therapy are partially or completely neglected, and the existing nomenclature is not used uniformly. Quality evaluation revealed flaws in many articles, concerning not only glucocorticoid-specific recommendations but also guideline quality in general. Conclusion: Current recommendations for use of glucocorticoids in the management of RA are suboptimal. More rigorous evaluation of doses, timing, and duration of their use is needed. Existing nomenclature on glucocorticoid therapy should be used uniformly.

AB - Objective: To describe the perception of the current role of systemic glucocorticoids in the management of rheumatoid arthritis (RA) by examining their importance and the current level of evidence in recent guidelines, and to identify open questions to be addressed in future guidelines and research projects. Methods: We conducted a systematic literature review using the databases Ovid Embase, PubMed Medline, and Cochrane Library for guidelines on the pharmacologic treatment of RA. Retrieved articles were evaluated regarding their quality using the Appraisal of Guidelines for Research and Evaluation II tool and scrutinized for all relevant information concerning the use of glucocorticoids. Results: All guidelines agree that glucocorticoids, especially if given at low doses and for a short duration, are an appropriate option in the treatment of RA. However, many recommendations remain vague, as reliable and detailed evidence is scarce. Important aspects of glucocorticoid therapy are partially or completely neglected, and the existing nomenclature is not used uniformly. Quality evaluation revealed flaws in many articles, concerning not only glucocorticoid-specific recommendations but also guideline quality in general. Conclusion: Current recommendations for use of glucocorticoids in the management of RA are suboptimal. More rigorous evaluation of doses, timing, and duration of their use is needed. Existing nomenclature on glucocorticoid therapy should be used uniformly.

UR - http://www.scopus.com/inward/record.url?scp=85023177893&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85023177893&partnerID=8YFLogxK

U2 - 10.1002/acr.23185

DO - 10.1002/acr.23185

M3 - Article

C2 - 28029750

AN - SCOPUS:85023177893

VL - 69

SP - 1134

EP - 1141

JO - Arthritis and Rheumatology

JF - Arthritis and Rheumatology

SN - 2326-5191

IS - 8

ER -